Trials / Unknown
UnknownNCT05072886
Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis
A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Followed by an Open-Label Extension to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Topical AT193 in the Treatment of Patients With Nail Psoriasis
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Azora Therapeutics Australia Pty Ltd · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in approximately 34 patients with nail psoriasis for 16 weeks. Part 2 is an open-label extension phase where all patients will receive active drug for an additional 16 weeks followed by a 2 week nontreatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT193 | Topical applied to affected areas daily |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2021-10-11
- Last updated
- 2023-01-25
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT05072886. Inclusion in this directory is not an endorsement.